News & Events

    • Latest News
  • What Drives Us
  • Leadership
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • The Science of Chronokines
    • Proteomic Discovery: Chronokines
    • Our Focus: Critical Diseases of Aging
  • Pipeline
    • Clinical Progress
    • AKST4290: Targeting Eotaxin
    • GRF6019 & GRF6021: Selected Plasma Fractions
    • AKST1210: Targeting Beta-2 Microglobulin
    • Clinical Trials
  • News & Events
    • Latest News
    • Publications & Presentations
  • Careers & Culture
    • Life at Alkahest
    • Benefits of Joining the Alkahest Family
    • Join Our Team in Making a Difference
  • Partners & Partnering
    • Current Partnerships
    • Partnering with Alkahest
  • Contact

Grifols to Make a Major Equity Investment in Alkahest

« Back to News

View Press Release (Grifols)

© 2023 Alkahest, Inc. All rights reserved. All images property of their respective owners. Cookie Policy | Privacy Policy.
Therapies Born from the Science of Plasma®
Alkhest Logo

This website uses cookies to improve your browsing experience and analyze site traffic. By using our site, you consent to our use of cookies, in accordance with our cookie policy.I Understand

MENU
  • What Drives Us
  • Leadership
    • Our Team
    • Board of Directors
    • Scientific Advisory Board
  • Science
    • The Science of Chronokines
    • Proteomic Discovery: Chronokines
    • Our Focus: Critical Diseases of Aging
  • Pipeline
    • Clinical Progress
    • AKST4290: Targeting Eotaxin
    • GRF6019 & GRF6021: Selected Plasma Fractions
    • AKST1210: Targeting Beta-2 Microglobulin
    • Clinical Trials
  • News & Events
    • Latest News
    • Publications & Presentations
  • Careers & Culture
    • Life at Alkahest
    • Benefits of Joining the Alkahest Family
    • Join Our Team in Making a Difference
  • Partners & Partnering
    • Current Partnerships
    • Partnering with Alkahest
  • Contact